

# David Grimes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3408216/publications.pdf>

Version: 2024-02-01

20  
papers

551  
citations

1039880

9  
h-index

887953

17  
g-index

20  
all docs

20  
docs citations

20  
times ranked

794  
citing authors

#	ARTICLE	IF	CITATIONS
1	Co-designing a digital companion with people living with Parkinson's to support self-care in a personalized way: The eCARE-PD Study. <i>Digital Health</i> , 2022, 8, 205520762210816.	0.9	11
2	Investigating the contribution of white matter hyperintensities and cortical thickness to empathy in neurodegenerative and cerebrovascular diseases. <i>GeroScience</i> , 2022, 44, 1575-1598.	2.1	4
3	Small and Large Magnetic Resonance Imagingâ€“Visible Perivascular Spaces in the Basal Ganglia of Parkinson's Disease Patients. <i>Movement Disorders</i> , 2022, 37, 1304-1309.	2.2	11
4	Caregiving concerns and clinical characteristics across neurodegenerative and cerebrovascular disorders in the Ontario neurodegenerative disease research initiative. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	3
5	The Integrated Parkinsonâ€™s disease Care Network (IPCN): Qualitative evaluation of a new approach to care for Parkinsonâ€™s disease. <i>Patient Education and Counseling</i> , 2021, 104, 136-142.	1.0	7
6	Moving towards Integrated and Personalized Care in Parkinsonâ€™s Disease: A Framework Proposal for Training Parkinson Nurses. <i>Journal of Personalized Medicine</i> , 2021, 11, 623.	1.1	18
7	Return on Investment Analysis for the Integrated Parkinsonâ€™s Care Network: Lesson Learned from a Pilot Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1-7.	1.5	0
8	Contribution of rare variant associations to neurodegenerative disease presentation. <i>Npj Genomic Medicine</i> , 2021, 6, 80.	1.7	14
9	Association of apolipoprotein E variation with cognitive impairment across multiple neurodegenerative diagnoses. <i>Neurobiology of Aging</i> , 2021, 105, 378.e1-378.e9.	1.5	8
10	Patient-centred management of Parkinson's disease. <i>Lancet Neurology</i> , The, 2020, 19, 887-888.	4.9	2
11	Moving towards home-based community-centred integrated care in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 21-26.	1.1	27
12	Parkinson's Disease, <sc><i>NOTCH3</i></sc> Genetic Variants, and White Matter Hyperintensities. <i>Movement Disorders</i> , 2020, 35, 2090-2095.	2.2	18
13	Canadian guideline for Parkinson disease. <i>Cmaj</i> , 2019, 191, E989-E1004.	0.9	90
14	Reply to â€œStudying reproducibility of data-driven Parkinson's disease subtypesâ€• <i>Parkinsonism and Related Disorders</i> , 2019, 66, 245-246.	1.1	0
15	Development of the Integrated Parkinsonâ€™s Care Network (IPCN): using co-design to plan collaborative care for people with Parkinsonâ€™s disease. <i>Quality of Life Research</i> , 2019, 28, 1355-1364.	1.5	33
16	Reproducibility of data-driven Parkinson's disease subtypes for clinical research. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 102-106.	1.1	63
17	Caffeine as symptomatic treatment for Parkinson disease (CafÃ©-PD). <i>Neurology</i> , 2017, 89, 1795-1803.	1.5	102
18	Supplement 4: Canadian Guidelines on Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2012, 39, S1-S30.	0.3	103

#	ARTICLE	IF	CITATIONS
19	Deprenyl in Parkinson's Disease: Mechanisms, Neuroprotective Effect, Indications and Adverse Effects. Canadian Journal of Neurological Sciences, 1992, 19, 142-146.	0.3	34
20	Targeted copy number variant identification across the neurodegenerative disease spectrum. Molecular Genetics & Genomic Medicine, 0, , .	0.6	3